Danpanichkul Pojsakorn, Díaz Luis Antonio, Suparan Kanokphong, Tothanarungroj Primrose, Sirimangklanurak Supapitch, Auttapracha Thanida, Blaney Hanna L, Sukphutanan Banthoon, Pang Yanfang, Kongarin Siwanart, Idalsoaga Francisco, Fuentes-López Eduardo, Leggio Lorenzo, Noureddin Mazen, White Trenton M, Louvet Alexandre, Mathurin Philippe, Loomba Rohit, Kamath Patrick S, Rehm Jürgen, Lazarus Jeffrey V, Wijarnpreecha Karn, Arab Juan Pablo
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA.
Clin Mol Hepatol. 2025 Apr;31(2):525-547. doi: 10.3350/cmh.2024.0835. Epub 2025 Jan 9.
BACKGROUND/AIMS: Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and alcohol-attributable primary liver cancer between 2000-2021.
We registered the global and regional trends of AUD, ALD, and alcohol-related liver cancer using data from the Global Burden of Disease 2021 Study, the largest and most up-to-date global epidemiology database. We estimated the annual percent change (APC) and its 95% confidence interval (CI) to assess changes in age-standardized rates over time.
In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD, and 132,030 cases of alcohol-attributable primary liver cancer. Between 2000 and 2021, there was a 14.66% increase in AUD, a 38.68% increase in ALD, and a 94.12% increase in alcohol-attributable primary liver cancer prevalence. While the age-standardized prevalence rate for liver cancer from alcohol increased (APC 0.59%; 95% confidence interval [CI] 0.52 to 0.67%) over these years, it decreased for ALD (APC -0.71%; 95% CI -0.75 to -0.67%) and AUD (APC -0.90%; 95% CI -0.94 to -0.86%). There was significant variation by region, socioeconomic development level, and sex. During the last years (2019-2021), the prevalence, incidence, and death of ALD increased to a greater extent in females.
Given the high burden of AUD, ALD, and alcohol-attributable primary liver cancer, urgent measures are needed to prevent them at both global and national levels.
背景/目的：酒精是全球疾病负担的主要因素，包括酒精使用障碍（AUD）和酒精性肝病（ALD）。我们旨在评估2000年至2021年间AUD、ALD以及酒精所致原发性肝癌的全球负担。
我们利用全球疾病负担2021研究的数据，该研究是最大且最新的全球流行病学数据库，记录了AUD、ALD和酒精相关肝癌的全球及区域趋势。我们估计了年度百分比变化（APC）及其95%置信区间（CI），以评估年龄标准化率随时间的变化。
2021年，有1.1112亿例AUD病例、302万例ALD病例以及132,030例酒精所致原发性肝癌病例。2000年至2021年间，AUD增加了14.66%，ALD增加了38.68%，酒精所致原发性肝癌患病率增加了94.12%。虽然这些年酒精所致肝癌的年龄标准化患病率有所上升（APC为0.59%；95%置信区间[CI]为0.52至0.67%），但ALD（APC为-0.71%；95% CI为-0.75至-0.67%）和AUD（APC为-0.90%；95% CI为-0.94至-0.86%）的年龄标准化患病率有所下降。不同地区、社会经济发展水平和性别之间存在显著差异。在过去几年（2019 - 2021年），ALD的患病率、发病率和死亡率在女性中上升幅度更大。
鉴于AUD、ALD和酒精所致原发性肝癌的高负担，需要在全球和国家层面采取紧急措施来预防这些疾病。
